- Home
- DC vs PACB Comparison
DC vs PACB Comparison
Compare DC & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DC
- PACB
- Stock Information
- Founded
- DC 2017
- PACB 2000
- Country
- DC United States
- PACB United States
- Employees
- DC N/A
- PACB N/A
- Industry
- DC Precious Metals
- PACB Biotechnology: Laboratory Analytical Instruments
- Sector
- DC Basic Materials
- PACB Industrials
- Exchange
- DC Nasdaq
- PACB Nasdaq
- Market Cap
- DC 346.9M
- PACB 364.2M
- IPO Year
- DC N/A
- PACB 2010
- Fundamental
- Price
- DC $3.70
- PACB $1.29
- Analyst Decision
- DC Buy
- PACB Buy
- Analyst Count
- DC 1
- PACB 9
- Target Price
- DC $7.50
- PACB $2.06
- AVG Volume (30 Days)
- DC 785.1K
- PACB 10.1M
- Earning Date
- DC 08-12-2025
- PACB 08-06-2025
- Dividend Yield
- DC N/A
- PACB N/A
- EPS Growth
- DC N/A
- PACB N/A
- EPS
- DC N/A
- PACB N/A
- Revenue
- DC N/A
- PACB $152,357,000.00
- Revenue This Year
- DC N/A
- PACB $3.33
- Revenue Next Year
- DC N/A
- PACB $18.52
- P/E Ratio
- DC N/A
- PACB N/A
- Revenue Growth
- DC N/A
- PACB N/A
- 52 Week Low
- DC $1.84
- PACB $0.85
- 52 Week High
- DC $4.11
- PACB $2.72
- Technical
- Relative Strength Index (RSI)
- DC 54.62
- PACB 57.95
- Support Level
- DC $3.62
- PACB $1.14
- Resistance Level
- DC $3.85
- PACB $1.35
- Average True Range (ATR)
- DC 0.13
- PACB 0.10
- MACD
- DC -0.05
- PACB 0.00
- Stochastic Oscillator
- DC 16.33
- PACB 60.71
About DC Dakota Gold Corp.
Dakota Gold Corp is a gold exploration and development company with a specific focus on revitalizing the Homestake District in Lead, South Dakota. Dakota Gold has high-caliber gold mineral properties covering over 48 thousand acres surrounding the historic Homestake Mine. Company project includes Richmond Hill Project.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.